We treat colorectal cancer (colon and rectal), esophageal cancer, stomach (gastric) cancer, anal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma (hepatobiliary cancer), and neuroendocrine cancer.
Patients with GI cancers benefit from our refined approaches to risk assessment, advances to improve responses to existing treatments, and development of more effective treatments.
Our physicians specialize in the treatment of aggressive and complex GI cancers. The best approach for our patients depends on the tumor type, stage, and personal goals.
One or more of the following therapies may be recommended:
Download our Duke Cancer Patient Resource Guide.
To make an appointment, please call 888.275.3853. For more information on gastrointestinal cancer care at Duke Health, visit:
To find a doctor, visit Find A Specialist.
Our Gastrointestinal Cancer disease group is advancing translational research to bring about new treatments, improve the effectiveness of current treatments, and prevent or lessen treatment side effects.
Our physician scientists bring together clinical, translational and basic research to identify mechanisms of sensitivity, resistance, and toxicity to anti-cancer therapies.
Gerald Blobe, MD, PhD, is the lead physician-scientist engaged in preclinical research.
David Hsu, MD, PhD; Michael Morse, MD; Brent Hanks, MD, PhD; and Nicholas Devito, MD; are physician-scientists engaged in translational research. Andrew Nixon, PhD, is the lead scientist engaged in translational research.
Led by Brent Hanks, MD, PhD, this lab utilizes genetically engineered tumor model systems as well as clinical specimens to:
The Hanks Lab works to develop novel strategies to enhance the efficacy of checkpoint inhibitor and vaccine immunotherapy while also developing predictive biomarkers to better guide the management of cancer patients with immunotherapeutic agents. The lab's work in GI oncology is currently focused on understanding the role of autocrine and paracrine Wnt signaling in the establishment of immune tolerance and immunotherapy resistance.
The Hsu Lab
Led by David Hsu, MD, PhD, this lab is engaged in:
The Phase I Biomarker Laboratory, directed by Andrew Nixon, PhD, has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute.
We have an experienced team made up of physician-scientists, nurses, and in-patient staff as well as specialists engaged in protocol development and clinical trial registration.
Our main foci of clinical research are in esophageal/GE/gastric cancer (Hope Uronis, MD); hepatobiliary cancers (Michael Morse, MD); neuroendocrine cancer (Michael Morse, MD); pancreatic cancer (James Abbruzzese, MD, and Niharika Mettu, MD); and colorectal cancer (John Strickler, MD, David Hsu, MD, PhD, and Yousuf Zafar, MD, MHS).
Topics of correlative investigation include:
Our Center for Applied Cancer Health Policy, led by physician-scientist Yousuf Zafar, MD, MHS, investigates affordability and value of care, oncology reimbursement and care redesign, and behavioral science in cost and value.
Select active studies include:
We collaborate in health services research with Duke University’s Margolis Center for Health Policy, Duke Forge (Health Data Science Center), Fuqua School of Business, and the Sanford School of Public Policy.
If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact the Gastrointestinal (GI) Clinical Trials Office at 919.668.1861.
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More